For­mer Shkre­li com­pa­ny Tra­vere lands li­cens­ing deal with Vi­for on kid­ney drug

Just a month ago, the biotech for­mer­ly owned by con­vict­ed drug ex­ec Mar­tin Shkre­li saw promis­ing da­ta re­lat­ed to its kid­ney drug sparsen­tan from a 36-week treat­ment study. Now, Tra­vere is putting more of its weight be­hind the drug with a new li­cens­ing agree­ment.

Tra­vere is team­ing up with the Swiss phar­ma Vi­for in a joint col­lab­o­ra­tion and li­cens­ing agree­ment to com­mer­cial­ize sparsen­tan, a po­ten­tial drug for FS­GS and IgAN, in Eu­rope, Aus­tralia and New Zealand.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER